Prepared By
Anastasia Levov, MVDr, MRCVS
Effective detection of BRAFV595E mutation in canine urothelial and prostate carcinomas using immunohistochemistry
Leonore Aeschlimann, Alexandra Kehl, Franco Guscetti, Caroline Posthaus, Heike Aupperle-Lellbach, Sven Rottenberg, Simone de Brot.
Veterinary and Comparative Oncology, 2024; Vol 22: pp. 295–302
https://onlinelibrary.wiley.com/doi/full/10.1111/vco.12978
Background
This study evaluates the use of a BRAFV600E specific (VE1) antibody to detect the BRAFV595E mutation in canine urothelial carcinoma (UC) and prostate carcinoma (PC) using immunohistochemistry (IHC). In human medicine, IHC is routinely used to detect BRAFV600E mutations in various cancers, while in dogs, polymerase chain reaction (PCR), either quantitative (qPCR) or digital (ddPCR), is currently the only well-established method for identifying BRAFV595E.
This study demonstrates that IHC using a human BRAFV600E antibody reliably detects the BRAFV595E protein in canine urothelial and prostate tumours, offering a cost-effective and widely accessible alternative for mutation detection.
Study Design
A retrospective study conducted at multiple institutions. It examined formalin-fixed, paraffin-embedded (FFPE) tissue samples of canine UC and PC to assess the sensitivity and specificity of BRAFV600E IHC in detecting the canine BRAFV595E mutation, comparing the results with detection of BRAFV595E mutation using droplet digital PCR (ddPCR).
Animals
The study included 143 dogs: 122 with urothelial carcinoma (108 bladder, 14 urethra) and 21 with prostate carcinoma. Most UC cases were female (68%), 80% of PC cases were neutered males. The most common breeds were Labrador Retrievers, Cocker Spaniels, West Highland White Terriers, and Jack Russell Terriers. The median age at diagnosis was 10 years for UC and 9.5 years for PC.
Methods
This study analysed FFPE tissue samples from 122 canine UC cases and 21 PC cases. Bladder and urethral tumours were classified as either low- or high-grade UC based on the most recent canine grading system. Furthermore, these tumours were categorised based on their histomorphology as: (1) conventional urothelial, (2) urothelial with divergent differentiation or (3) other (anaplastic or other differentiation). Prostate tumours were categorised as (1) glandular (adenocarcinoma), (2) urothelial or (3) mixed (any combination of urothelial, glandular or other).
IHC was performed using a BRAFV600E-specific antibody to detect the canine BRAFV595E mutation. Intratumor staining was classified as either homogeneous (distributed regularly and evenly throughout the tumour tissue) or heterogeneous (regional staining differences with focal or multifocal negative areas).
To validate the IHC findings, ddPCR was used, testing all UC cases and only IHC-positive PC cases.
Results
The study found that BRAFV595E was present in 59% (72/122) of UC cases and 65% (14/21) of PC cases, a detection rate consistent with previous PCR-based studies in canine UC and PC. Immunohistochemistry (IHC) demonstrated high specificity (100%) and sensitivity (99%), showing strong concordance with droplet digital PCR (ddPCR). However, one low-grade UC case tested positive via ddPCR but negative by IHC.
Bladder and urethral tumours with conventional urothelial differentiation were significantly more likely to be BRAF-mutated compared to UC cases with divergent differentiation or non-urothelial histomorphology. Intratumor heterogeneity was rare, observed in 4% of UC cases, where regional variations in BRAF staining intensity were noted.
All non-neoplastic bladder and prostate tissues tested negative for BRAFV595E, reinforcing the mutation’s specificity for neoplastic tissues.
Important Findings
This study demonstrates that IHC using a BRAFV600E-specific antibody is a reliable and accurate method for detecting the BRAFV595E mutation in canine UC and PC. The findings establish IHC as a cost-effective and widely available alternative to PCR, particularly for large-scale cancer screening.
The study also highlights a strong correlation between tumour morphology and BRAF mutation status, with urothelial-type tumours more frequently exhibiting the mutation.
Study Limitations
A key limitation of this study is its retrospective design, as reliance on medical records can introduces potential inconsistencies. Additionally, unlike ddPCR, which can detect BRAF mutations in urine samples, IHC requires a tissue biopsy, making it a more invasive diagnostic tool with limited applicability in cases where obtaining a biopsy is challenging. Another limitation is that only IHC-positive PC cases underwent ddPCR testing, meaning that some IHC-negative cases may have been falsely classified as mutation-free. Furthermore, the sample size for PC was relatively small, which limits the statistical power to assess BRAF mutation prevalence and its clinical significance in prostate tumours.
Journal Reviewer Comments
The use of immunohistochemistry (IHC) for detecting BRAFV595E in canine urothelial and prostate carcinomas offers significant potential for advancing research into BRAF-targeted therapies.
Currently, BRAF inhibitors such as vemurafenib and dabrafenib have shown promise in human oncology, but their clinical efficacy in dogs remains underexplored. By providing a cost-effective and widely accessible method for identifying BRAF-mutant tumours, IHC enables large-scale screening of canine patients, which is essential for selecting candidates for clinical trials evaluating BRAF inhibitors.

Leave a Reply
Want to join the discussion?Feel free to contribute!